Cue Biopharma Inc (CUE)
1.05
+0.02
(+1.94%)
USD |
NASDAQ |
Nov 22, 16:00
1.05
0.00 (0.00%)
After-Hours: 16:43
Cue Biopharma Debt to Equity Ratio: 0.2086 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
September 30, 2024 | 0.2086 |
June 30, 2024 | 0.289 |
March 31, 2024 | 0.2399 |
December 31, 2023 | 0.2202 |
September 30, 2023 | 0.2138 |
June 30, 2023 | 0.2191 |
March 31, 2023 | 0.1825 |
December 31, 2022 | 0.1522 |
September 30, 2022 | 0.1961 |
June 30, 2022 | 0.1659 |
March 31, 2022 | 0.1525 |
December 31, 2021 | 0.00 |
September 30, 2021 | 0.00 |
Date | Value |
---|---|
June 30, 2021 | 0.00 |
March 31, 2021 | 0.00 |
December 31, 2020 | 0.00 |
September 30, 2020 | 0.00 |
June 30, 2020 | 0.00 |
March 31, 2020 | 0.00 |
December 31, 2019 | 0.00 |
September 30, 2019 | 0.00 |
June 30, 2019 | 0.00 |
March 31, 2019 | 0.00 |
December 31, 2018 | 0.00 |
September 30, 2018 | 0.00 |
June 30, 2018 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
0.289
Maximum
Jun 2024
0.112
Average
0.1523
Median
Debt to Equity Ratio Benchmarks
Biomarin Pharmaceutical Inc | 0.1098 |
Arbutus Biopharma Corp | 0.00 |
GlycoMimetics Inc | -- |
FibroGen Inc | -0.2987 |
Cidara Therapeutics Inc | -- |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 44.81M |
Total Liabilities (Quarterly) | 19.44M |
Shareholders Equity (Quarterly) | 25.37M |
Current Ratio | 2.219 |
Net Debt Paydown Yield | 2.10% |